1.1Drug enclosed in a liposome
A phospholipid bilayer encloses the drug, and a lipid anchor holds the antibody on the outer surface. The antibody binds a cell-surface antigen, and lysosomal degradation of the internalized liposome releases the drug.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
A phospholipid bilayer encloses the drug, and a lipid anchor holds the antibody on the outer surface. The antibody binds a cell-surface antigen, and lysosomal degradation of the internalized liposome releases the drug.
Freeze-drying a conjugate solution containing sucrose produces an amorphous solid that limits molecular mobility during storage. Water dissolves the matrix and reconstitutes the conjugate for administration.
A covalent linker joins the folate ligand to a cytotoxic payload. Cell-surface folate receptors bind the ligand and internalize the conjugate, and cleavage of an acid-sensitive bond in the endosome releases the payload.
A macrocyclic chelator attached to the antibody coordinates a beta-emitting lutetium ion. The antibody binds its target, and beta particles emitted by the ion deposit energy in nearby tissue.
A haloacetamide group on the release module reacts with the cysteine thiol to form a thioether. After cellular uptake, cleavage within the release module liberates the payload.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Use the anti-NaPi2b conjugate with its bioactive payload as a reference reagent in an ex vivo renal toxicology assay. Apply the conjugate to the apical side of polarized renal epithelial cultures with measured surface NaPi2b expression. Measure uptake by antibody staining and compare viability with cultures exposed to the free payload or the unconjugated antibody.
Replace the L3 peptide with a beta-D-glucuronide trigger linked to a para-hydroxybenzyl spacer at L4. Connect the antibody-side linker through a pendant handle on the spacer and attach an amine-bearing payload through a benzylic carbamate. Lysosomal beta-glucuronidase removes the glucuronide and exposes the phenol, which initiates spacer fragmentation and releases the payload.
Replace L1 with a discrete polyethylene glycol spacer containing eight ethylene oxide units. Place a maleimide at the antibody-facing end for coupling to an exposed antibody cysteine and an amine at the distal end for amide coupling to a carboxyl-bearing L2 connector. Position the L3 peptide and the L4-payload assembly downstream of L2.
Prepare two conjugate preparations with the same antibody, linker, and payload. Use hydrophobic interaction chromatography to collect species bearing two, four, and six payloads per antibody, and verify each fraction by intact mass spectrometry. Use the four-payload fraction for one preparation and blend the two- and six-payload fractions at a one-to-one antibody molar ratio for the other, giving both preparations a mean loading of four.
Integrate the conjugate with a two-channel microfluidic culture system that separates a perfused endothelial channel from a chamber containing NaPi2b-positive tumor spheroids. Deliver the conjugate through the endothelial channel and collect outlet samples at fixed intervals. Measure intact conjugate and released payload in the outlet and image the spheroids to track antibody penetration and cell death.
Connect a hydrophobic interaction chromatography system to an automated fraction collector and analyze collected fractions by intact mass spectrometry. Software calculates mean drug loading for each fraction from the relative abundances of the resolved loading species. The software combines these measurements with protein concentrations to select pooling volumes that meet a specified mean loading and a maximum allowable fraction of unconjugated antibody.
One engineered cysteine on each heavy chain provides two conjugation sites per intact antibody. A thiol-reactive linker attaches one payload at each site, and intact-mass spectrometry measures the occupancy distribution.
A synthetic peptide-derived tubulin inhibitor carries an amine that forms a carbamate with the linker. Intracellular linker cleavage releases the inhibitor, which binds tubulin and suppresses microtubule polymerization.
A spacer with four ethylene glycol repeats separates the antibody attachment site from the downstream linker units. The ether oxygens hydrate the spacer, and functional groups at both ends provide covalent attachment points.
An azide on the extension unit reacts with a terminal alkyne on the adjoining linker segment in a copper-catalyzed cycloaddition. The resulting 1,2,3-triazole forms a covalent connection between the segments.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
The silica-based biomolecule carrier comprises a porous core; a first bioactive moiety; a second bioactive moiety functionally associated with the first bioactive moiety; and linkers for respectively conjugating the first bioactive moiety and the second bioactive moiety to the porous core.A · US 2018/0228918 A1 · abstract
The three components (an antibody, a cytotoxin and a linker) of an ADC constitute a targeted drug delivery system, in which the construction and optimization of linkers are crucial for the development of such system.B · US 2021/0230218 A1 · ¶ 2
The first bioactive moiety and the second bioactive moiety are different from yet functionally associated with each other and may be independently selected from an enzyme, an antibody, a catalytic mimetic, a ligand, a hormone, a biomolecule-binding protein, and a functional fragment thereof, such as a peptide or polypeptide.A · US 2018/0228918 A1 · ¶ 5
For example, bioactive moieties may be formed from synthetic, recombinant or isolated peptides and proteins such as antibodies, antigens, synthetic small molecule peptidomimetics, receptor ligands, enzymes, adhesion peptides, nucleotides, polynucleic acids such as DNA and antisense nucleic acid molecule, activated sugars and polysaccharides, and organic drug molecules.A · US 2018/0228918 A1 · ¶ 20
The product obtained by removing Teoc protection as described above is often used as part of the linker to be covalently linked to the drug moiety in the preparation of antibody-drug conjugate.B · US 2021/0230218 A1 · ¶ 62
In order to achieve covalent linking to the antibody moiety, the said product is often coupled with a connector via the following specific reaction routes:B · US 2021/0230218 A1 · ¶ 62
Among them, oligopeptide linkers (such as valine-citrulline dipeptide (Val-Cit, VC)) have been widely used in various ADC drugs.B · US 2021/0230218 A1 · ¶ 3
An empty cell means only that no passage was reproduced there.
However, due to the limitations of some existing approaches, particularly regarding cellular uptake, targeting and delivery issues, there is a need to explore more satisfactory solutions.A · US 2018/0228918 A1 · ¶ 4
The two different and functionally-associated biomolecules are thus co-delivered into the cells at the same time.A · US 2018/0228918 A1 · ¶ 8
However, lower amines are usually used in this method to remove the Fmoc protecting group, so that byproducts are easily formed and hard to completely remove.B · US 2021/0230218 A1 · ¶ 7
However, transition metal, usually Pd, is required as the catalyst when removing the Cbz protecting group in this method, which is harmful to the human body by resulting in heavy metal residues which is hard to remove.B · US 2021/0230218 A1 · ¶ 9
patent.fyi, US 2026/0355332 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355332/, SHA-256 01cdcfeb662bb7ff9c99bc1aa4351c80d7c455552b30ecc0d279cbca1bc67f8e